Skip to Main Content

Paper Details

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
0
2024
Author NameAffiliation
Heiko Sch??derMemorial Sloan Kettering Cancer Center
  • 1 - 1

Datasets

Release 1.2